Trial · NCT07884513
Acute Effects of Ketone Monoester Co-Ingestion With Dietary Protein on Whole-Body Phenylalanine Oxidation, Phenylalanine Retention, and Myofibrillar Protein Breakdown Following Resistance Exercise in Older Males
NCT07884513, Not applicable, Not yet recruiting, McGill University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acute Effects of Ketone Monoester Co-Ingestion With Dietary Protein on Whole-Body Phenylalanine Oxidation, Phenylalanine Retention, and Myofibrillar Protein Breakdown Following Resistance Exercise in Older Males. Trials, record NCT07884513. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884513
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Acute Effects of Ketone Monoester Co-Ingestion With Dietary Protein on Whole-Body Phenylalanine Oxidation, Phenylalanine Retention, and Myofibrillar Protein Breakdown Following Resistance Exercise in Older Males
- NCT number
- NCT07884513
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 18 participants, estimated
- Lead sponsor
- McGill University
- Conditions
- Ketosis, Resistance Exercise, Dietary Protein, Aging, Anabolic Resistance, Post-exercise Period
- Interventions
- Ketone Monoester + Dietary Protein (KET+PRO), Dietary Protein (PRO), Resistance Exercise
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phenylalanine Oxidation | 0-360 minutes in the postprandial period | Quantification of whole-body phenylalanine oxidation using 13CO2 enrichment measured in breath samples following ingestion of labeled phenylalanine. |
| Primary | Phenylalanine Retention | 0-360 minutes in the postprandial period | Quantification of whole-body phenylalanine retention calculated as the difference between phenylalanine intake and total exogenous phenylalanine oxidation following ingestion of labeled phenylalanine. |
| Secondary | Incremental area under the curve for total amino acid concentration | 60 minutes pre-prandial to 360 minutes postprandial | Incremental area under the curve for plasma total amino acid concentrations (mmol/L), including: histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, aspartic acid, cystine, glutamic acid, glycine, proline, serine and tyrosine , measured from repeated blood samples collected throughout 1-hour pre-prandial period and 6-hour postprandial recovery period. |
| Secondary | Time-course data for total amino acid concentration | 60 minutes pre-prandial to 360 minutes postprandial | Changes in plasma concentration of total amino acid concentration (μmol/L) including: free leucine, isoleucine, valine, histidine, lysine, methionine, phenylalanine, threonine, tryptophan, arginine, glutamine, glycine, alanine, serine, glutamic acid, aspartic acid, asparagine, tyrosine, cysteine, proline (combined), measured at 18 time points (t = -60, 0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 270, 300, 330, 360 minutes). |
| Secondary | Incremental area under the curve for essential amino acid concentration | 60 minutes pre-prandial to 360 minutes postprandial | Incremental area under the curve (iAUC) for plasma essential amino acid concentration (μmol/L) including free leucine, isoleucine, valine, histidine, lysine, methionine, phenylalanine, threonine, tryptophan (combined), measured across the 1-hour pre-prandial period and 6-hour postprandial period. |
| Secondary | Time-course data for essential amino acid concentration | 60 minutes pre-prandial to 360 minutes postprandial | Changes in plasma concentration of essential amino acid (μmol/L) including: free leucine, isoleucine, valine, histidine, lysine, methionine, phenylalanine, threonine, tryptophan (combined), measured at 18 time points (t = -60, 0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 270, 300, 330, 360 minutes). |
| Secondary | Incremental area under the curve for branched chain amino acid concentration | 60 minutes pre-prandial to 360 minutes postprandial | Incremental area under the curve (iAUC) for plasma branched chain amino acid concentration (μmol/L) including free leucine, isoleucine and valine measured across the 1-hour pre-prandial period and 6-hour postprandial period. |
| Secondary | Time-course data for branched chain amino acid concentration | 60 minutes pre-prandial to 360 minutes postprandial | Changes in plasma concentration of branched chain amino acid (μmol/L) including: free leucine, isoleucine and valine measured at 18 time points (t = -60, 0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 270, 300, 330, 360 minutes). |
| Secondary | Incremental area under the curve for leucine concentration | 60 minutes pre-prandial to 360 minutes postprandial | Incremental area under the curve (iAUC) for plasma leucine concentration (μmol/L) measured across the 1-hour pre-prandial period and 6-hour postprandial period. |
| Secondary | Time-course data for leucine concentration | 60 minutes pre-prandial to 360 minutes postprandial | Changes in plasma concentration of leucine (μmol/L) measured at 18 time points (t = -60, 0, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 270, 300, 330, 360 minutes). |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884513
GET https://conductscience.org/api/trials/v1/NCT07884513/registered